Biotest AG: Biotest AG opens fifth plasma collection centre in Czech Republic

DGAP-News: Biotest AG / Key word(s): Miscellaneous
30.06.2021 / 07:00
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest AG opens fifth plasma collection centre in Czech Republic

- 24 plasma collection centres in Europe to ensure long-term plasma supply

Dreieich, 30 June 2021. Biotest has received the operating license for its fifth plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre is located in the historic centre of the South Bohemian city of Budweis.

In the state-of-the-art centre with 15 donor beds, donors can watch TV or use WLAN during donation. The centre is open 6 days a week for up to 12 hours a day.

Biotest is continuing on its planned path to expand its own donation stations in order to increase its plasma collection capacity. The plasma from the additional centre will be used to support to future growth at the new production facility in Dreieich.

"We are very pleased to open another state-of-the-art collection station in the Czech Republic. I would like to thank all plasma donors who continue to donate at our centres during the pandemic and also our dedicated employees," emphasizes Dr Martin Reinecke, Senior Vice President Global Plasma Alliances and Protein Supply at Biotest AG.

The collected plasma is processed exclusively at Biotest AG in Dreieich. Audits conducted regularly in the Czech Republic ensure that the high legal and internal quality requirements are met.

About human blood plasma
Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

30.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de